| Year |
Citation |
Score |
| 2005 |
Yang D, Bierman J, Tarumi YS, Zhong YP, Rangwala R, Proctor TM, Miyagoe-Suzuki Y, Takeda S, Miner JH, Sherman LS, Gold BG, Patton BL. Coordinate control of axon defasciculation and myelination by laminin-2 and -8. The Journal of Cell Biology. 168: 655-66. PMID 15699217 DOI: 10.1083/Jcb.200411158 |
0.466 |
|
| 2005 |
Rangwala R, Banine F, Borg JP, Sherman LS. Erbin regulates mitogen-activated protein (MAP) kinase activation and MAP kinase-dependent interactions between Merlin and adherens junction protein complexes in Schwann cells. The Journal of Biological Chemistry. 280: 11790-7. PMID 15659388 DOI: 10.1074/Jbc.M414154200 |
0.485 |
|
| 2002 |
Sherman LS, Struve JN, Rangwala R, Wallingford NM, Tuohy TM, Kuntz C. Hyaluronate-based extracellular matrix: keeping glia in their place. Glia. 38: 93-102. PMID 11948803 DOI: 10.1002/glia.10053 |
0.421 |
|
| 2002 |
Wobus M, Rangwala R, Sheyn I, Hennigan R, Coila B, Lower EE, Yassin RS, Sherman LS. CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society For Applied Immunohistochemistry. 10: 34-9. PMID 11893033 DOI: 10.1097/00129039-200203000-00006 |
0.457 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2019 |
Hong DS, Tehrani OS, Safran H, Steuer CE, Lacy J, Taylor MH, George TJ, Rangwala RA, Jain S, Viana Nicacio L, Cho MT. SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors. Journal of Clinical Oncology. 37: TPS3160-TPS3160. DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS3160 |
0.178 |
|
| 2015 |
Brahmer JR, Kim ES, Zhang J, Smith MM, Rangwala RA, O'Brien ME. KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1). Journal of Clinical Oncology. 33: TPS8103-TPS8103. DOI: 10.1200/JCO.2015.33.15_SUPPL.TPS8103 |
0.162 |
|
| 2002 |
Barton LF, Cruz M, Rangwala R, Deepe GS, Monaco JJ. Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection. Journal of Immunology (Baltimore, Md. : 1950). 169: 3046-52. PMID 12218120 DOI: 10.4049/Jimmunol.169.6.3046 |
0.132 |
|
| 2015 |
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, ... ... Rangwala R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine. 372: 2018-28. PMID 25891174 DOI: 10.1056/Nejmoa1501824 |
0.13 |
|
| 2016 |
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, ... ... Rangwala R, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine. PMID 27718847 DOI: 10.1056/NEJMoa1606774 |
0.125 |
|
| 2015 |
Soria J, Flatten O, Horn L, Felip E, Gandhi L, Hui R, Hellmann M, Leighl N, Zhang J, Kondic A, Rangwala R, Lubiniecki G, Garon E. 33LBA Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001 European Journal of Cancer. 51: S726-S727. DOI: 10.1016/S0959-8049(15)30077-0 |
0.12 |
|
| 2017 |
Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28168303 DOI: 10.1093/annonc/mdx008 |
0.112 |
|
| 2015 |
Mok T, Wu Y, Sadowski S, Zhang J, Rangwala R, de Lima Lopes G. 481TiP Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study Annals of Oncology. 26: ix125. DOI: 10.1093/annonc/mdv532.65 |
0.109 |
|
| 2016 |
Aggarwal C, Abreu DR, Felip E, Carcereny E, Gottfried M, Wehler T, Ahn M, Dolled-Filhart M, Zhang J, Shentu Y, Rangwala R, Piperdi B, Baas P. Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024 Annals of Oncology. 27: vi363. DOI: 10.1093/ANNONC/MDW378.14 |
0.109 |
|
| 2014 |
Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy. 10: 1380-90. PMID 24991834 DOI: 10.4161/Auto.29264 |
0.106 |
|
| 2017 |
Garon E, Reck M, Rodríguez-Abreu D, Robinson A, Hui R, Tibor C, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Turner D, ... ... Rangwala R, et al. P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S1290-S1291. DOI: 10.1016/J.JTHO.2016.11.1825 |
0.102 |
|
| 2019 |
Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer J, Jones R, Forster M, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, ... Rangwala RA, et al. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31796521 DOI: 10.1158/1078-0432.CCR-19-2962 |
0.099 |
|
| 2015 |
Mok T, Wu Y, Watson PA, Zhang J, Rangwala RA, Lopes G. Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: TPS8105-TPS8105. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps8105 |
0.099 |
|
| 2015 |
Rizvi NA, Garon EB, Leighl N, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Rangwala RA, Lubiniecki G, Zhang J, Emancipator K, Roach CM, Rutledge R, Hui R, Ahn M, et al. Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001. Journal of Clinical Oncology. 33: 8026-8026. DOI: 10.1200/JCO.2015.33.15_SUPPL.8026 |
0.098 |
|
| 2017 |
Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, ... ... Rangwala R, et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. The Lancet. Oncology. PMID 29129441 DOI: 10.1016/S1470-2045(17)30690-3 |
0.095 |
|
| 2019 |
de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, ... ... Rangwala RA, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. The Lancet. Oncology. PMID 30745090 DOI: 10.1016/S1470-2045(18)30859-3 |
0.095 |
|
| 2014 |
Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian JT, Troxel AB, Tan KS, Heitjan DF, DeMichele AM, Vaughn DJ, Redlinger M, et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy. 10: 1391-402. PMID 24991838 DOI: 10.4161/Auto.29119 |
0.093 |
|
| 2014 |
Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel AB, Evans TL, DeMichele AM, Nathanson KL, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 10: 1369-79. PMID 24991839 DOI: 10.4161/Auto.29118 |
0.087 |
|
| 2017 |
Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, Zhao GQ, Rangwala RA, Matei D. Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028. Journal of Clinical Oncology. 35: 5513-5513. DOI: 10.1200/Jco.2017.35.15_Suppl.5513 |
0.083 |
|
| 2017 |
Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017745471. PMID 29095678 DOI: 10.1200/JCO.2017.74.5471 |
0.076 |
|
| 2016 |
Reck M, Rodríguez-Abreu D, Robinson A, Hui R, Csoszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby M, Lubiniecki G, ... ... Rangwala R, et al. KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50% Annals of Oncology. 27: vi578. DOI: 10.1093/ANNONC/MDW435.40 |
0.075 |
|
| 2021 |
Fuh KC, Bookman MA, Liu JF, Coleman RL, Herzog TJ, Thaker PH, Monk BJ, Anderson R, McIntyre G, Rangwala R, Moore KN. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecologic Oncology. PMID 34474927 DOI: 10.1016/j.ygyno.2021.08.020 |
0.071 |
|
| 2014 |
Herzog T, Kutarska E, Bidzinski M, Symanowski J, Nguyen B, Rangwala R, Naumann R. Adverse event profile by folate receptor status for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer Gynecologic Oncology. 133: 178. DOI: 10.1016/j.ygyno.2014.03.469 |
0.067 |
|
| 2019 |
Mahdi H, Schuster SR, O'Malley DM, McNamara DM, Rangwala RA, Liang S, Jain S, Nicacio L, Chon HS. Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208). Journal of Clinical Oncology. 37: TPS5602-TPS5602. DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS5602 |
0.064 |
|
| 2016 |
Herzog TJ, Kutarska E, Bidzińsk M, Symanowski J, Nguyen B, Rangwala RA, Naumann RW. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 27654255 DOI: 10.1097/IGC.0000000000000806 |
0.064 |
|
| 2021 |
Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindeløv SD, Chen M, Harris JR, Smith M, ... ... Rangwala R, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. The Lancet. Oncology. PMID 33845034 DOI: 10.1016/S1470-2045(21)00056-5 |
0.063 |
|
| 2018 |
Concin N, Vergote IB, Lassen UN, Drew Y, Machiels JP, Arkenau HT, Forster MD, Jones R, Johnson ML, Slomovitz BM, Spicer J, Cornez N, Gennigens C, Coleman RL, Windfeld K, ... ... Rangwala RA, et al. A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii344. PMID 32136816 DOI: 10.1093/Annonc/Mdy285.170 |
0.06 |
|
| 2017 |
Brahmer JR, Rodriguez-Abreu D, Robinson AG, Hui R, Csõszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, McLean J, ... ... Rangwala RA, et al. Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. Journal of Clinical Oncology. 35: 9000-9000. DOI: 10.1200/JCO.2017.35.15_SUPPL.9000 |
0.055 |
|
| 2019 |
Hong D, Arkenau H, de Bono J, Lassen U, Drew Y, Slomovitz B, Ghatta S, Windfeld K, Rangwala R, Concin N. Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623) Gynecologic Oncology. 154: 11-12. DOI: 10.1016/J.YGYNO.2019.04.034 |
0.051 |
|
| 2018 |
Coleman RL, Concin N, Herzog TJ, Woelber LL, Mirza MR, Monk BJ, Cibula D, Lorusso D, González-Martín A, Windfeld K, Lammerts van Bueren J, Vindeloev SD, Rangwala RA, Vergote I. A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer. Journal of Clinical Oncology. 36: TPS5601-TPS5601. DOI: 10.1200/jco.2018.36.15_suppl.tps5601 |
0.051 |
|
| 2014 |
Naumann R, Bidzinski M, Lovejoy C, Anderson K, Rangwala R, Kutarska E. CA-125 as a response marker for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: The PRECEDENT trial Gynecologic Oncology. 133: 177-178. DOI: 10.1016/j.ygyno.2014.03.468 |
0.04 |
|
| 2016 |
Mok T, Wu YL, Sadowski S, Zhang J, Rangwala R, Kush D, Lopes Gde L. 195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S142. PMID 27198333 DOI: 10.1016/S1556-0864(16)30304-5 |
0.038 |
|
| 2017 |
Satouchi M, Hotta K, Nosaki K, Takahashi T, Nakagawa K, Aoe K, Noguchi K, Shimamoto T, Rangwala R, Brahmer J. Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: ix73. PMID 32120654 DOI: 10.1093/annonc/mdx619 |
0.037 |
|
| 2016 |
De Lima Lopes G, Wu YL, Sadowski S, Zhang J, Rangwala R, Kush D, Mok T. P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894): Track: Immunotherapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S244-S245. PMID 27676577 DOI: 10.1016/J.Jtho.2016.08.114 |
0.033 |
|
| 2017 |
Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Deitz AC, Lubiniecki GM, ... ... Rangwala R, et al. PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024 Journal of Thoracic Oncology. 12: S8-S9. DOI: 10.1016/J.JTHO.2016.11.010 |
0.026 |
|
| Hide low-probability matches. |